
Zvolte si etiketu
zobrazeno přímo na lahvičceLaboratorní zpráva
PDF- Testováno
- Tamoxifen (Nolvadex) 20mg × 100 Tabs
- Laboratoř
- Analiza Białek
- Datum
- October 2026
- Výsledek
- 20.34 mg per tablet (20 mg label)
- Č. objednávky
- Heslo
Testováno nezávisle, ověřitelné heslem přímo v laboratoři.
Tamoxifen (Nolvadex)
PCT & AI
- Laboratorně testováno
- Odesíláme z Německa
Objednávka
- DHL se sledováním zásilky
- Diskrétní balení
V kostce
Tamoxifen (Nolvadex) v číslech
Klíčové údaje z našeho lexikonu.
Celé heslo v lexikonu- Class
- SERMestrogen receptor modulator
- Half-life
- longseveral days
- Use
- Oraldaily
- Sizes
- 10 to 20 mg2 sizes in the shop
What studies show
The source in the lexiconTamoxifen and anastrozole for preventing gynecomastia under bicalutamide (opens in a new tab)
Boccardo et al., Journal of Clinical Oncology, 2005
Hodnocení
Co říkají zákazníci
Jen skutečné objednávky, které obsahovaly Tamoxifen (Nolvadex).
Všechna hodnoceníZnalosti
Vše o Tamoxifen (Nolvadex)
Podrobné informace připravujeme.
Is tamoxifen approved?
Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.
How well did tamoxifen prevent gynecomastia in the trial?
114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.
Why was anastrozole weaker?
Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.
What does the meta-analysis show?
Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.
Are there data on gynecomastia of unknown cause?
A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.
What happened to the hormones?
Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).
Srovnání
Srovnání s ostatními
Související
Související produkty
Clomid (Clomifen)
Léky · Po cyklu (PCT) a inhibitory aromatázy Po cyklu (PCT) a inhibitory aromatázy
2 velikosti
Aromasin (Exemestane)
Léky · Po cyklu (PCT) a inhibitory aromatázy Po cyklu (PCT) a inhibitory aromatázy
2 velikosti
Arimidex (Anastrozole)
Léky · Po cyklu (PCT) a inhibitory aromatázy Po cyklu (PCT) a inhibitory aromatázy
2 velikosti
Letrozol (Femara)
Léky · Po cyklu (PCT) a inhibitory aromatázy Po cyklu (PCT) a inhibitory aromatázy
2 velikosti
Laboratorně testováno
Tamoxifen (Nolvadex)
